Unsafe
Not Aligned
Patient Risk:
Low
Summary
The claim about patent expiration is not supported by the provided FDA-approved prescribing information excerpts and cannot be verified against the label.
Category Scores
Accurate Statements
Unsupported Statements
Gemtesa (vibegron) patents are expected to expire in 2027.
The provided prescribing information excerpts do not contain any statement regarding patent status or expected patent expiration dates.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claim is about patent expiration and does not directly affect prescribing, safety, dosing, contraindications, or monitoring as described in the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Introduces non-label information (patent expiration date) that is not supported by the provided FDA-approved prescribing information.
Suggested Improvement
Remove the patent expiration prediction or replace it with information explicitly supported by authoritative sources; do not present it as label-supported.